Gordon Pointe Acquisition Corp. Announces Extension
by Matt Cianci on 2020-06-15 at 7:28pm

Today, Gordon Pointe Acquisition Corp. (GPAQ) announced that it had elected to extend the deadline to consummate its proposed business combination with HOF Village, LLC (“HOFV”) (presentation link) to July 15, 2020. As previously disclosed, GPAQ had amended its amended and restated certificate of incorporation to extend the date by which GPAQ must consummate its initial business combination from May 14, 2020 to June 15, 2020, plus an option by GPAQ to further extend such date for an additional thirty days to July 15, 2020.  In connection with such extension, on June 12, 2020, GPAQ’s sponsor contributed to GPAQ $0.04 for each of GPAQ’s public shares outstanding, for an aggregate contribution of $114,937.76.  Not a bad deal for arb and yield investors getting an additional 40bps in yield (~4.9% annualized) on a 30 day “risk-free” investment.  The amount was deposited into GPAQ’s trust account established in connection with GPAQ’s initial public offering. GPAQ now has until July 15, 2020 to consummate its proposed business.

GPAQ also announced today that, in light of continued public health concerns regarding the Coronavirus, or COVID-19, that GPAQ shareholders of record may participate telephonically in the special shareholders meeting (the “Special Meeting”) to approve the proposed business combination with HOFV scheduled for June 30, 2020 at 10:00 A.M. Eastern.  GPAQ shareholders may participate in the call by dialing 1-646-558-8656, Entry Code: 798-121-0979 and Passcode: 882333.

GPAQ shareholders are entitled to participate in and vote at the Special Meeting to approve the proposed extension if they were a shareholder of record as of the close of business on June 1, 2020, or hold an appropriate legal proxy for the meeting provided by their broker, bank or other nominee.

Whether or not a shareholder plans to attend the Special Meeting telephonically, GPAQ urges its shareholders to vote and submit their proxy in advance of the Special Meeting by one of the methods described in the proxy statement/prospectus. Instructions as to how to vote at the Special Meeting will be provided on the conference call.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved